Gender Differences in Periprocedural and Long-term Outcomes in Patients with Hypertrophic Cardiomyopathy Treated with Alcohol Septal Ablation Therapy: A Single Center Retrospective Study

Basit Öğe Kaydı
dc.contributor.authorÇolak, Ayşe
dc.contributor.authorBaşkurt, Ahmet Anıl
dc.contributor.authorKumral, Zeynep
dc.contributor.authorDursun, Hüseyin
dc.contributor.authorÖzpelit, Ebru
dc.contributor.authorAkdeniz, Bahri
dc.contributor.authorBarış, Nezihi
dc.date.accessioned2025-03-20T09:45:09Z
dc.date.available2025-03-20T09:45:09Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesi
dc.description.abstractBackground and Aim: We aim to demonstrate the periprocedural and long-term results of alcohol septal ablation (ASA) treatment in patients with hypertrophic cardiomyopathy (HCM) and specify the differences between female and male patients. Materials and Methods: We enrolled 53 consecutive patients with HCM who underwent ASA treatment. Preprocedural demographic data, pre- and postprocedural characteristics and complications, echocardiographic data, and long-term results, including all-cause mortality and major adverse cardiovascular events (MACE), were recorded. MACE was defined as sudden cardiac death due to ventricular arrhythmias or heart failure (HF) and rehospitalizations due to HF or atrial fibrillation after the procedure. Results: The mean age was 56.4 ± 12.1 years and 29 (54.7%) of the patients were female. Age at the time of ablation was higher (P = 0.04), and the presentation New York Heart Association functional class (P = 0.03) was worse in female patients. The median volume of ethanol usage was higher in male patients (P = 0.03) and the median duration of intensive care unit stay was higher in female patients (P = 0.02). The overall survival rates after ASA at 1, 5, 10, and 12 years were 96%, 87%, 76%, and 76%, respectively. There was no difference in the overall survival rates between genders (log-rank P = 0.4) and MACE was significantly higher in women patients (log-rank P = 0.03). Conclusion: Women patients with HCM were older and had a worse functional capacity during the ASA procedure. Despite the similar mortality rates between genders, MACE was higher in women after the procedure. Earlier evaluation and treatment in female patients might decrease MACE during follow-up after ASA treatment. © Copyright 2023 by the Cardiovascular Academy Society / International Journal of the Cardiovascular Academy published by Galenos Publishing House.
dc.identifier.doi10.4274/ijca.2023.29392
dc.identifier.endpage73
dc.identifier.issn2405-819X
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85196354622
dc.identifier.scopusqualityQ4
dc.identifier.startpage66
dc.identifier.urihttps://doi.org/10.4274/ijca.2023.29392
dc.identifier.urihttps://hdl.handle.net/20.500.14034/2149
dc.identifier.volume9
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherGalenos Publishing House
dc.relation.ispartofInternational Journal of the Cardiovascular Academy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250319
dc.subjectalcohol septal ablation
dc.subjectGender differences
dc.subjecthypertrophic cardiomyopathy
dc.subjectmajor adverse cardiovascular events
dc.subjectmortality
dc.subjectsex differences
dc.titleGender Differences in Periprocedural and Long-term Outcomes in Patients with Hypertrophic Cardiomyopathy Treated with Alcohol Septal Ablation Therapy: A Single Center Retrospective Study
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu